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Lähtökohta: Raskauteen liittyvät trofoblastisairaudet, mukaan lukien rypäleraskaus, invasiivinen moola ja 
korionkarsinooma eli istukkasyöpä sekä istukkapedin trofoblastituumori, ovat monimutkaisia, 
hoitamattomana hengenvaarallisia tautitiloja. Aikaisempien tutkimusten mukaan pienten riskien taudeissa 
parantumisprosentti on nykyään lähes 100 % ja suurten riskin taudeissa 85–94 %. Tämän tutkimuksen 
tarkoituksena oli selvittää, vastaavatko Tampereen yliopistollisessa sairaalassa (TAYS) saavutetut 
hoitotulokset aikaisemmissa tutkimuksissa esitettyjä paranemisprosentteja.  
Metodit: Tutkimus perustui vuosien 2002–2013 sairaskertomuksiin, joissa ICD‒10 diagnoosinumerona oli 
käytetty yhtä tai useampaa seuraavista: rypäleraskaus (ICD‒10: O01), invasiivinen moola (D39.2), 
korionkarsinooma (C58) tai istukkapedin trofoblastituumori (D39.2). Kun tutkimukseen soveltumattomat 
tapaukset, kuten ne, joissa oli käytetty väärää diagnoosinumeroa, poissuljettiin, aineisto koostui yhteensä 78 
sairaskertomuksesta. Kerättäessä dataa trofoblastitautien jälkeisistä raskauksista, kaikki keräämishetkellä 
(syksy 2014) saatavilla oleva informaatio sisällytettiin mukaan.  
Tulokset: 75,6 % tapauksista oli ei-neoplastisia raskaudenaikaisia trofoblastitauteja, kattaen 36 täydellistä 
rypäleraskautta ja 23 osittaista rypäleraskautta. Loput 24,4 % tapauksista oli neoplastisia trofoblastitauteja: 
13 persistenttiä moolaa, 3 invasiivista moolaa ja 3 korionkarsinoomaa. Aineistoon ei sisältynyt yhtään 
istukkapedin trofoblastituumoria. Suurin osa hyvänlaatuisista tapauksista kaavittiin vain kerran (91,2 %) ja 
pahanlaatuisista tapauksista kerran kaavittiin 47,4 %. Huomattavasti suurempi määrä maligneja tapauksia 
(36,8 %) vaati toisen kaavinnan benigneihin tapauksiin verrattuna (8,8 %). Lisäksi yhden malignin tapauksen 
yhteydessä ei kaavintaa suoritettu kertaakaan, ja kahden malignin tapauksen yhteydessä kaavinta suoritettiin 
kolmesti. Suurimmalla osalla (67,3 %) benigneistä tapauksista hCG-arvot normalisoituivat ensimmäisen 
kahden kuukauden aikana kaavinnan jälkeen. Vastaavasti maligneissa tapauksissa suurimalla osalla (78,9 %) 
hCG-arvojen normalisoituminen tapahtui kahden ja neljän kuukauden välillä kaavinnan jälkeen. Ensisijainen 
hoito pienen riskin neoplastisille taudeille oli yksittäinen solusalpaajahoito, joko metotreksaatilla tai 
aktinomysiini D:llä toteutettuna. Suuren riskin taudit puolestaan hoidettiin ensisijaisesti 
yhdistelmäsolusalpaajahoidolla, EMA/CO:lla. Ensisijainen solusalpaaja vaihdettiin toiseen solusalpaajan 
yhteensä kuudesti, johtuen joko ensisijaisen solusalpaajan puutteellisesta tehosta tai sivuvaikutuksista. 
Solusalpaajiin kuvattiin liittyneen lukuisia erilaisia sivuvaikutuksia, jotka suurimmaksi osaksi vastasivat 
aikaisemmassa kirjallisuudessa kuvattuja lääkeainekohtaisia sivuvaikutuksia. Yhdistelmähoitoon (EMA/CO) 
liittyi lisäksi kolme vakavampaa haittavaikutusta. Yksi potilas kärsi ohimenevästä näön menetyksestä, jonka 
aiheutti metotreksaatti. Toisella potilaalla taas diagnosoitiin sekä syvä laskimotukos että akuutti leukemia. 
Molemmat potilaat kuitenkin toipuivat haittavaikutuksista, eikä pitkäaikaista haittaa jäänyt. Kaikki 
Tampereen yliopistollisessa sairaalassa hoidetut, raskauteen liittyvää trofoblastitautia sairastaneet potilaat 
paranivat eikä kuolemantapauksia esiintynyt yhtään. Lisäksi yhteensä noin 74 % hoidetuista potilaista on 
synnyttänyt trofoblastitaudin jälkeen tai oli raskaana dataa kerättäessä (syksy 2014).  
Päätelmät: Kaikki TAYS:ssa vuosina 2002–2013 hoidetut, trofoblastitautia sairastaneet potilaat paranivat 
eikä trofoblastitaudeista tai niiden hoidosta jäänyt potilaille pitkäaikaishaittoja. Voidaan siis todeta, että 
TAYS:ssa saavutetut hoitotulokset vastaavat aikaisemmassa kirjallisuudessa esitettyjä paranemisprosentteja. 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––  
TABLE OF CONTENTS  
 
1 ABSTRACT .................................................................................................................................................. 1 
2 INTRODUCTION ........................................................................................................................................ 2 
2.1 Definition of gestational trophoblastic diseases .................................................................................. 2 
2.2 Epidemiology and risk factors .............................................................................................................. 2 
2.3 Pathogenesis ........................................................................................................................................... 3 
2.4 Clinical presentation ............................................................................................................................. 3 
2.5 Diagnosis ................................................................................................................................................. 4 
2.6 Classification of malignant trophoblastic diseases ............................................................................. 5 
2.7 Treatment ............................................................................................................................................... 5 
2.8 Follow-up ................................................................................................................................................ 7 
3 METHODS .................................................................................................................................................... 9 
4 RESULTS .................................................................................................................................................... 11 
5 DISCUSSION .............................................................................................................................................. 19 
6 CONCLUSIONS ......................................................................................................................................... 21 
7 REFERENCES ........................................................................................................................................... 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
1 ABSTRACT  
 
 
 
Objective. Gestational trophoblastic diseases (GTD), including hydatidiform mole, invasive mole, 
choriocarcinoma and placental-site trophoblastic tumor, are complex diseases that can be fatal if not treated. 
According to previous studies, cure rates are nowadays excellent, approaching almost 100% with low-risk 
diseases and 85-94% with high-risk diseases. The purpose of this study was to determine whether cure rates 
achieved in treatment of GTDs in Tampere University Hospital (Tampereen Yliopistollinen Keskussairaala, 
TAYS later in this study) are similar to cure rates described in other studies.  
Methods. The study was based on the medical records between years 2002 and 2013 that included an ICD-10 
diagnosis number for hydatidiform mole (O01), invasive mole (D39.2), choriocarcinoma (C58) or placental-
site tumor (D39.2). After excluding unsuitable cases, such as cases with wrong diagnosis number, the 
research data included 78 valid cases. When collecting data concerning successful pregnancies after 
gestational trophoblastic diseases, all data available until the collection date (autumn 2014) was included.  
Results. 75.6% of the cases were non-neoplastic gestational trophoblastic diseases, including 36 complete 
moles and 23 partial moles. The rest, 24.4% of the cases, were neoplastic GTDs, including 13 persistent 
moles, 3 invasive moles and 3 choriocarcinomas. The data included no placental-site trophoblastic tumors. 
Majority of both benign (91.2%) and malignant cases (47.4%) were evacuated only once, but a notably larger 
amount of malignant cases (36.8%) needed two evacuations, compared to benign cases evacuated twice 
(8.8%). In addition, there was one neoplastic case that was not evacuated at all, and two cases where 
evacuation was performed three times. With the majority of the malignant cases (78.9%), it took two to four 
months after evacuation for the hCG level to normalize, whereas with about two-thirds of the benign cases, 
the hCG level normalized within two months after evacuation. The primary treatment for the low-risk 
neoplastic diseases was single-agent chemotherapy with either methotrexate or actinomycin D 
(dactinomycin), whereas high-risk cases were primarily treated with multidrug EMA/CO treatment. Six 
times the primary chemotherapy had to be replaced by alternative chemotherapy because of the side effects 
or inadequate efficiency. Most of the side effects of different chemotherapies found in TAYS were similar to 
the side effects described in other studies. In addition, three more severe complications occurred with 
patients treated with EMA/CO. One patient suffered from a transient loss of vision caused by methotrexate, 
and another one was diagnosed with both leukemia and phlebothrombosis. Fortunately, no long-term harm 
was caused by these. All the patients treated at TAYS got disease free, and no deaths occurred. Additionally, 
74% of the patients have given birth after GTD, or were pregnant when the data was collected (autumn 
2014). 
Conclusion. All the patients treated at TAYS between years 2002 and 2013 were cured, and no long-term 
harm was caused by either the trophoblastic disease or its treatment. Based on the results of this study, it can 
be affirmed that cure rates achieved at TAYS are comparable to cure rates described in other studies. 
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2 INTRODUCTION 
 
 
2.1 Definition of gestational trophoblastic diseases 
 
Hydatidiform mole, invasive mole and choriocarcinoma are gestational trophoblastic diseases. Hydatidiform 
mole is a premalignant disorder and can be considered to be either complete or partial. Hydatidiform mole 
can become an invasive mole if it penetrates into the myometrium. Invasive mole can also metastasize 
especially to lungs and vagina. Choriocarcinoma can develop after molar pregnancy or any other pregnancy. 
Its characteristics include remarkable changes of placental tissue, and metastasizing to other organs. Both 
invasive mole and choriocarcinoma are considered to be malignant, neoplastic disorders. Malignant 
gestational trophoblastic diseases also include placental-site trophoblastic tumor and its variant, an 
epithelioid trophoblastic tumor. Both of these disorders are rare.(1, 2, 5, 6, 8) The term persistent mole, used 
in this study, stands for a hydatidiform mole that has not invaded into the myometrium, but its management 
requires chemotherapy and thus it is considered to be a neoplastic disorder as well.  
2.2 Epidemiology and risk factors  
 
The incidence of a gestational trophoblastic disease, both benign and malignant, varies within regions. 
Incidences in Europe (including Finland), North America, New Zealand and Australia are lower than 
incidences in Southeast Asia and Japan, for example. (2, 5, 6, 7, 8, 9) In Scandinavia, for example, in 
Norway and Sweden, the incidence of a hydatidiform mole is less than one per 1000 pregnancies (2) whereas 
in Japan and Southeast Asia, the incidence of a hydatidiform mole is 2‒10 per 1000 pregnancies, depending 
on the source (2, 8). The incidence of choriocarcinoma in Europe and North America is approximately 1 per 
40 000 pregnancies and in Southeast Asia and Japan higher at 9.2 per 40 000 pregnancies. However, the 
incidence rates of hydatidiform mole and choriocarcinoma have both declined in all populations over the past 
30 years.(2) 
Some risk factors for hydatidiform mole have been established. These are the extremes of maternal age (< 20 
years old, > 40 years old) (2, 8, 9) and antecedent pregnancy being a molar pregnancy. The risk of molar 
pregnancy is also increased among women with history of miscarriages.(2, 8) Advanced maternal age and a 
prior complete hydatidiform mole are considered to be risk factors for choriocarcinoma. The risk of 
choriocarcinoma after a complete molar pregnancy is over a thousand times greater than with other 
pregnancies.(8) 
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2.3 Pathogenesis  
 
A surplus of chromosomes inherited from father is typical for a hydatidiform mole. The development of a 
complete hydatidiform mole usually requires an ovum without maternal chromosomes that is fertilized by 
sperm with duplicated genome, hence producing androgenetic karyotype 46XX. In some rare cases, a 
complete hydatidiform mole is developed by two sperms fertilizing an empty ovum, in which case karyotype 
can be either 46XY or 46XX. A partial hydatidiform mole usually arises when a seemingly healthy ovum is 
fertilized by two sperms, producing a triploid karyotype.(5) Absence of fetus or embryo and diffuse swelling 
of villi and trophoblastic hyperplasia are typical pathological features for a complete hydatidiform mole (8). 
In a partial mole, a fetus/embryo is developed but it is abnormal and therefore inviable (6, 8). In addition, in 
partial mole swelling of villi and trophoblastic hyperplasia is focal. 15‒20% of complete hydatidiform moles 
and 5% of partial moles develop into some neoplastic trophoblastic disorder (invasive mole or 
choriocarcinoma).(8) 
When a hydatidiform mole penetrates into the myometrium, a malignant invasive mole has developed. 
Swollen villi and hyperplasia of trophoblasts are typical pathological features of an invasive mole (2,8). 
Approximately 15% of invasive moles metastasize to vagina or lungs. Typical for an invasive mole is that 
the diagnosis is usually clinical instead of pathological and treatment can be started without a 
histopathological analysis.(8) 
Hyperplasia and anaplasia of syncytiotrophoblasts and cytotrophoblasts, absence of villi, hemorrhage and 
necrosis are pathological characteristics for a choriocarcinoma (4, 8). Choriocarcinoma penetrates rapidly 
trough the myometrium, and metastasizes to other organs, such as lungs, liver, brain and vagina. 
Choriocarcinoma is more common after molar pregnancy than other pregnancies, such as term or preterm 
gestation or tubal pregnancy.(8) Approximately 2‒3% of hydatidiform moles develop into choriocarcinoma 
(8, 9).   
A placental-site tumor and its variant, an epithelioid trophoblastic tumor are both very rare trophoblastic 
diseases (8). Whereas hydatidiform mole and choriocarcinoma originate from villous trophoblasts, a 
placental-site tumor arises from interstitial trophoblast (5). A placental-site trophoblastic tumor can develop 
after any type of pregnancy. Comparing to choriocarcinoma, a placental-site tumor arises more slowly, 
metastasizes later and produces less hCG, and unlike choriocarcinoma, primary management of placental-
site tumor is surgical.(5) 
2.4 Clinical presentation 
 
The most common symptom of a complete hydatidiform mole is vaginal bleeding. Other typical symptoms 
are the too large size of the uterus in relation to pregnancy weeks and hyperemesis. Pregnancy induced 
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hypertension can also be one of the symptoms, but nowadays it is rare because molar pregnancies are 
typically diagnosed earlier. In addition, bilateral enlarged theca lutein cysts of the ovaries are occasionally 
present. Vaginal bleeding is characteristic also for a partial hydatidiform mole.(8) The size of the uterus is 
usually normal or too small in relation to pregnancy weeks, and symptoms are similar to missed or 
incomplete abortion (2, 6, 8). Other, quite rare symptoms of a hydatidiform mole are hyperthyroidism, 
anemia, and toxemia of pregnancy (6). The symptoms mainly result from an elevated hCG level, which is 
usually higher in a complete hydatidiform mole (over 100 000 IU/l) than in a partial mole (under 100 000 
IU/l) (4, 6, 8). 
Malignant disorders may have varying clinical presentations depending on the type of the pregnancy 
preceding the malignancy and the extent of disorder (8). Vaginal bleeding is a common symptom, especially 
when antecedent pregnancy has been a molar pregnancy (2, 8). Postmolar neoplasm should be suspected if 
after evacuation of a molar pregnancy, the uterus is too large, or if irregular bleeding or bilateral ovarian 
enlargement exists (4, 6). The patient may also suffer from stomach pains (2). Other symptoms can be, for 
example, cough, hemoptysis and dyspnea caused by lung metastasis or headache, hemiplegia or seizures 
caused by brain metastasis (2, 8). Uterine bleeding and subinvolution are symptoms of postpartum 
choriocarcinoma (8).  
2.5 Diagnosis 
 
When diagnosing gestational trophoblastic diseases, the two most important examinations are pelvic 
ultrasonography and quantitative measurement of human chorionic gonadotropin (hCG) in serum and, if 
necessary, in urine (2, 4, 5, 6, 8). Characteristic findings for a complete hydatidiform mole are high 
concentration of hCG in serum, and so-called snowstorm image seen in pelvic ultrasonography (2, 5, 6), 
which is caused by heterogenic mass filling uterine cavity (5, 6). Typically, no fetus can be found. When it 
comes to the partial mole, cystic focal changes and typically abnormal fetus can be seen in 
ultrasonography.(6, 8) The hCG level in a partial mole is usually not as elevated as in a complete mole (8).   
Postmolar gestational trophoblastic neoplasia can be diagnosed by elevating or plateauing concentrations of 
hCG after evacuation of hydatidiform mole. Non-molar choriocarcinomas are also usually diagnosed by an 
elevated hCG level. Discovery of metastasis is also an important part of choriocarcinoma’s diagnostics 
whether it is post- or non-molar.(8) In differential diagnosis of trophoblastic diseases, the ratio between the 
concentrations of free-β-hCG and total hCG can be used. If the ratio is above 5%, the disorder can be 
considered to be choriocarcinoma.(2, 7) Certain radiological studies are a part of the diagnosis of gestational 
trophoblastic neoplasia. To rule out lung metastasis, a chest x-ray and, in some cases, a CT-scan of the chest 
should be performed. Brain metastasis can be ruled out by either CT-scan or MRI-scan of the brain and for 
abdominal metastasis, abdominal CT-scan is put into practice.(1, 2, 5)    
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2.6 Classification of malignant trophoblastic diseases 
 
When classifying trophoblastic neoplasia and estimating their risk, two criteria can be used. The 
International Federation of Gynecology and Obstetrics (FIGO) has defined a staging criteria for gestational 
trophoblastic neoplasia. It has four stages from I to IV, which describe the anatomic distribution of the 
disorder (table 1). Another classification criteria used is a risk factor scoring system created by World Health 
Organization (WHO). It is a system where risk factors like mother’s age, antecedent pregnancy and 
pretreatment hCG are rated with score from 0 to 4 (0, 1, 2, 4). The more significant the risk factor, the higher 
the score. Individual scores are then added together and if the total score is under 7, the disorder is 
considered to be low risk, but if the total score is 7 or above, the disorder is considered to be high-risk (Table 
2).(1, 2, 5, 6)   
Table 1: FIGO staging criteria (1) 
FIGO staging criteria  Explanation 
Stage I Disease that has confined to the uterus  
Stage II Disease that has extended out of the uterus, but is 
limited to genital structures 
Stage III Disease that has metastasized to the lungs 
Stage IV Disease that has metastasized to any other sites 
 
2.7 Treatment 
 
Hydatidiform moles, both partial and complete, are primarily treated with suction curettage, which allows 
patients to maintain their fertility. Another option for treatment is hysterectomy, if fertility is not wished to 
be maintained.(2, 8) Because of residual tissue sometimes left behind, occasionally suction curettage needs 
to be performed twice or rarely even more times.  
Primary treatment for gestational trophoblastic neoplasia is chemotherapy. Choosing the treatment is based 
on classifying the disorders by their stage and risk-factor score (FIGO, WHO) to either a low- or high-risk 
disease. Low-risk diseases are primarily treated with single-agent chemotherapy, whereas high-risk diseases 
are treated with multidrug therapy.(1, 2, 3, 5) (Table 2) 
A low-risk disease is a disease that has confined to uterus (stage I), or a disease that has extended to genitals 
or metastasized to lungs (stage II or III), but has a total risk-factor score under 7 (WHO) (Table 2). Low-risk 
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diseases are managed with monochemotherapy, using either methotrexate or actinomycin D 
(dactinomycin).(1, 3) Because actinomycin D has more toxic side effect profile than methotrexate, it is 
usually the secondary option after methotrexate (1). There are several different protocols for methotrexate 
therapy, with varying doses, schedules and routes of administration. One of the most used protocols is 
methotrexate 0,4 mg/kg (maximum 25 mg) IV or IM given daily for five days every other week. Another 
used protocol is to give a higher dose of methotrexate (1 mg/kg/d, IM) every other day (days 1, 3, 5, 7) and 
to give folinic acid (0.1 mg/kg/d) on days 2, 4, 6 and 8 with at least one week separating the courses.(1, 2) If 
the used chemotherapy is actinomycin D, the protocol is to give 10‒13 µg/kg/d (IV) for 5 days every other 
week (1).  
With all the protocols, cycles of chemotherapy are continued until the hCG values have returned to normal, 
and at least one cycle is given after that. With single-agent chemotherapy, cure rates for low-risk diseases 
approach 100%.  Sometimes, a low-risk disease does not respond to single-agent chemotherapy as wished. 
An alternative single-agent therapy is started if the hCG level plateaus above normal, or if toxicity makes it 
impossible to use adequate doses or frequency. A multidrug therapy is started if the hCG level rises 
significantly, if new metastasis appear, or if a resistance to single-agent chemotherapy has developed.(1)  
A high-risk disease is a disease that has metastasized to genitals or to lungs (stages II or III) with a total risk-
factor score of 7 or above, or a disease that has metastasized to any other site (stage IV) (Table 2). High-risk 
diseases are primarily treated with multidrug chemotherapy. Nowadays, the most commonly used 
combination is called EMA/CO, which consists of etoposide, methotrexate (with folinic acid), actinomycin 
D, cyclophosphamide and vincristine.(1, 2, 3) EMA/CO was introduced in the 1980’s, and it has resulted in 
improved long-term survival rates in high-risk cases, nowadays being 85‒94%.(1, 2, 3, 7) EMA/CO schedule 
is the following: On day number one patient receives etoposide (100 mg/m2 IV), actinomycin D (0.5 mg IV) 
and methotrexate (300 mg/m2 IV for 12 h), on day number two patient is given etoposide (100 mg/m2 IV), 
actinomycin D (0,5 mg IV) and folinic acid (15 mg PO/IM for 12 h, 4 doses), and on day number eight 
patient receives cyclophosphamide (600 mg/m2 IV) and vincristine (1 mg/m2 IV). This cycle is repeated 
every other week. These cycles are continued until the hCG level has normalized, and 2‒3 times after that. 
Metastasis can be simultaneously treated with irradiation or surgery, depending on their location. If the 
disease does not respond to EMA/CO as hoped, other types of multidrug combinations can be used.(1) 
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Table 2: Classification and treatment of trophoblastic neoplasia (1) 
 Stage (FIGO) Risk factor score 
(WHO) 
Chemotherapy  
Low risk I  - Single-agent therapy 
(methotrexate or 
actinomycin D)  
II or III  < 7  
High risk II or III ≥ 7 Multidrug therapy 
(EMA/CO)  IV - 
 
Most common side effects of methotrexate are stomatitis (1), mucositis, myelosuppression, rise of 
aminotransferase levels, and pleural pain (2). Alopecia and nausea are not common side effects (1, 3). As 
mentioned earlier, actinomycin D has more toxic side effect profile than methotrexate, and it is often 
associated with alopecia, nausea (1, 3, 4) and vomiting (4). It can also cause local tissue damage if IV 
extravasation occurs (1, 3). EMA/CO’s side effects are nausea, hair loss and myelosuppression (2) because of 
the usage of both methotrexate and actinomycin D. Neither methotrexate, actinomycin D nor EMA/CO 
affects patient’s fertility (1, 2, 5) and they do not increase the incidence of congenital malformations in 
subsequent pregnancies (5).  
2.8 Follow-up 
 
 
After evacuation of a hydatidiform mole, serum hCG level is regularly measured to see whether the 
concentration reduces fast enough. This enables detecting trophoblastic sequelae, invasive mole or 
choriocarcinoma, as early as possible. In addition to measuring hCG level in serum, clinical findings, such as 
the size of the uterus and cessation of the bleeding after evacuation, should be considered when estimating 
the healing process of a hydatidiform mole.(8)  
After a low-risk trophoblastic disease, regular measurements of serum hCG level continue for 12 months 
after the hCG value has normalized, so that possible relapse of the disorder can be noticed as soon as 
possible (1). The hCG level also needs to be regularly checked after a high-risk disease. In Finland, the 
follow-up of high-risk diseases treated with multidrug therapy lasts five years altogether.(2)  
In addition to measuring the hCG level regularly, physical examinations should be performed in intervals of 
6‒12 months during the follow-up after the trophoblastic neoplasia. Contraception, preferably oral 
substances, should be started during the treatment and maintained at least one year after the completion of 
the chemotherapy. Additionally, pelvic ultrasound should be performed in the first trimester of subsequent 
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pregnancy, to confirm a normal gestation. The placentas from subsequent pregnancies should be examined 
histopathologically, and serum hCG level measured six weeks after any pregnancy.(1) 
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3 METHODS 
 
 
This study is a retrospective cohort study based on medical records of gestational trophoblastic diseases 
treated at Tampere University Hospital between years 2002 and 2013. Medical records were selected based 
on ICD‒10 diagnosis number, so that eventually all cases of hydatidiform moles (O01), invasive moles 
(D39.2), choriocarcinomas (C58) and placental-site trophoblastic tumors (D39.2) were included. When 
collecting data concerning successful pregnancies after gestational trophoblastic diseases, all data available 
until the collection date (autumn 2014) was included.  
Medical records were analyzed and information regarding the mother, the current gestational trophoblastic 
disease, the treatment of the GTD and the healing process was collected (Table 3).  
Table 3: Information gathered from the medical records 
Information gathered from the medical records  
Mother   Age 
Pevious gestations 
Previous parturitions  
Current trophoblastic disease (hCG) Pre- and post-treatment hCG-values 
Time it took for the hCG level to normalize 
Current trophoblastic disease (treatment) Number of evacuations needed 
Type of chemotherapy used 
Additional treatments (surgery) used  
Current trophoblastic disease (complications) Side effects and complications  
Subsequent pregnancies  Relapse of gestational trophoblastic disease 
Following pregnancies (normal/abnormal, successful 
or not)  
 
Some of the medical records were invalid and therefore excluded from the data. Reasons for invalidity were, 
for instance, incorrect use of GTD diagnosis numbers (ICD‒10) for other disorders invalid for this study, and 
for suspicions of molar pregnancies, which turned out to be non-molar. In addition, total of three cases were 
ruled out because of inadequate information. These cases were consultations from other hospitals, and the 
patients were mainly treated elsewhere. After excluding invalid cases, a total of 78 valid cases remained, 
including two cases where the diseases relapsed. These cases were analyzed separately as their own cases.  
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The normalization of hCG level was analyzed by dividing cases to four categories depending on the time (in 
months) it took for the level to normalize: x ≤ 2, 2 < x ≤ 4, 4 < x ≤ 6, x > 6. Hydatidiform moles were 
categorized either as complete or partial moles. Cases that were separated to be neither complete nor partial 
in the medical records, were considered to be complete moles. When analyzing malignant, neoplastic 
disorders, they were divided to persistent moles, invasive moles or choriocarcinomas. A persistent mole was 
considered to be a hydatidiform mole that had not penetrated into the myometrium, but chemotherapy was 
required for its treatment, whereas an invasive mole accounted for a mole that had invaded into the 
myometrium. 
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4 RESULTS 
 
 
The research data included 78 cases with two relapsed cases, making it altogether 76 patients suitable for this 
study. These patients were suffering from gestational trophoblastic diseases and were treated at TAYS 
between years 2002 and 2013. 59 (75.6%) cases were benign hydatidiform moles, 36 of these being complete 
and 23 partial moles. The rest of the cases, 19 (24.4%), were neoplastic: 13 persistent moles, 3 invasive 
moles and 3 choriocarcinomas. All the choriocarcinomas and one of the invasive moles were considered to 
be high-risk diseases, whereas all the persistent moles and the other two invasive moles were low-risk 
diseases. All neoplastic cases were post-molar, except one of the choriocarcinomas, which was a postpartum 
case following a full-term pregnancy. Only two of the persistent moles followed a partial mole, whereas with 
other neoplastic cases, the antecedent pregnancy was a complete mole. There were no placental-site tumors 
treated at TAYS between 2002 and 2013.  
 
Table 4: Frequencies of the disorders in relation to their antecedent pregnancy 
 
Disorder 
Total Benign 
 
Choriocarcinoma 
Invasive 
mole Persistent mole 
Antecedent 
pregnancy 
Complete mole Count 36                         2          3 11 52 
                      
Full-term 
pregnancy 
Count -                         1 - - 1 
      
Partial mole Count 23                         - - 2 25 
                        
Total Count 59                         3 3 13 78 
% within all 
the cases  
75.6%                3.85%             3.85.% 16.7%     100% 
 
The mean age among the mothers at the time of the GTD diagnosis was 29.6 years. When including only 
hydatidiform moles and persistent moles in the data, a total of 23.6% of the patients belong to a group with 
increased risk because of the age. 11.1% of these patients were 20 years old or younger, and 12.5% were 40 
years old or older. Out of all cases, the youngest patient was 16 years old with a complete mole, whereas the 
oldest patient was 54 years old with a persistent mole.   
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All the hydatidiform moles treated at TAYS were primarily managed with suction curettage. 91.2% of all 
hydatidiform moles were treated with only one suction curettage, and the rest 8.8%, needed to be evacuated 
twice. 47.4% of neoplastic disorders were evacuated only once, 36.8% twice, and 10.5% three times. There 
was also one neoplastic disorder (invasive mole) that was not evacuated at all, instead, chemotherapy was 
started immediately, because the case was a relapsed one. Two non-neoplastic cases had to be excluded from 
the analysis due to inadequate information regarding performed evacuations.  
Table 5: Number of evacuations needed  
 
Number of evacuations needed Total 
0 1 2 3  
Malignant/benign  Malignant Count 1 9 7 2 19 
% within malignant 
cases 
5.3% 47.4% 36.8% 10.5% 100.0% 
Benign 
(hydatidiform 
mole) 
Count 0 52 5 0 57 
% within benign cases 
0.0% 91.2% 8.8% 0.0% 100.0% 
Total Count 1 61 12 2 76 
% within all the cases 
1.3% 80.3% 15.8% 2.6% 100.0% 
 
The mean value of the hCG level before the first evacuation was 211 113 IU/l (SD: 244 498) including all 
the valid cases. The highest value preceding the first evacuation was over 1 000 000 IU/l. The patient in 
question had a partial mole, which developed into a persistent mole. The lowest value was 1 200 IU/l 
belonging to a patient with a partial mole treated with one evacuation. Altogether 11 cases had to be ruled 
out of the analysis because the information regarding their pretreatment hCG level was not available due to 
the initiation of the treatment in some other hospital. In addition, some of the excluded cases were initially 
diagnosed to be miscarriages, and therefore the hCG level was not measured before the evacuation. The 
average value before the evacuation number two was 10 586 IU/l, including both benign and malignant 
disorders that required second evacuation. The highest value was 29 211 IU/l and lowest 208 IU/l, both with 
partial moles. One case had to be excluded from the analysis because of inadequate information regarding 
hCG values. No connection between the pretreatment hCG level and the need for a second evacuation was 
found.  
Altogether 19 neoplastic cases were treated with chemotherapy. The research data included 15 low-risk 
disorders and 4 high-risk disorders (Table 2). At TAYS, low-risk disorders were primarily treated with 
single-agent chemotherapy (either methotrexate or actinomycin D), whereas high-risk disorders were 
managed with multidrug chemotherapy (EMA/CO), just like described in other studies (1, 2, 3, 4, 5). 
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In 13 of the low-risk cases, the treatment was initiated with methotrexate. There were two methotrexate 
protocols used: a smaller dosage of methotrexate (0.4 mg/kg/d, maximum 25 mg/d, IM or IV) given on days 
1-5, with cycles of 14 days, or higher dosage of methotrexate (1 mg/kg/d IM or IV) given on days 1, 3, 5, 
and 7 with folinic acid (0.1 mg/kg/d) given on days 2, 4, 6, and 8 every other week. The latter of the 
protocols was slightly more used: 8 patients out of 13 were treated with it. 9 out of these 13 cases were 
carried out with only methotrexate. In other cases, methotrexate had to be changed to another type of 
chemotherapy. Twice, actinomycin D was initiated because of difficult side effects of methotrexate. Once, 
methotrexate was changed to actinomycin D, which in turn was changed to multidrug therapy (EMA/CO), 
because the response for single-agent therapy was too weak. Once, EMA/CO was started after a couple of 
methotrexate cycles because of inadequate efficiency of methotrexate. The maximum of methotrexate cycles 
needed was 9 and the minimum 3‒4, when it was the only drug used. One of the low-risk cases was treated 
only using actinomycin D for 5 days (0.5 mg/d IV), every other week for 5 cycles. Once a relapsed case, 
classified as a low-risk disease, was treated with EMA/CO straight from the beginning, and only the last two 
cycles, after normalization of the hCG level, were carried out with methotrexate because of the difficult side 
effects caused by the multidrug therapy.  
All of the high-risk cases were initially treated with multidrug therapy EMA/CO consisting of etoposide (100 
mg/m2 IV; days 1‒2), methotrexate (300 mg/m2 IV for 12 h; day 1), actinomycin D (0.5 mg IV; days 1‒2), 
folinic acid (15 mg x 2 PO; days 2‒3), cyclophosphamide (600 mg/m2 IV; day 8) and vincristine (1 mg/m2 
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IV; day 8) given every other week. Once methotrexate had to be stopped, because it caused a transient loss of 
vision, and the treatment was at the end carried out as EA/CO. The rest of the high-risk cases were 
successfully treated with EMA/CO. When treating the high-risk diseases, the maximum of EMA/CO cycles 
required was 8 and the minimum 4.  
The normalization of the hCG level was categorized into four different groups depending on the time (in 
months) it took for the concentrations to normalize (below 5 IU/l): x ≤ 2, 2 < x ≤ 4, 4 < x ≤ 6, x > 6.  
 
Histogram 1: Normalization of hCG in months (benign cases)  
 
Histogram 1 shows that 67.3% (37) of the benign cases belong to the first group, with a normalized hCG 
level within the first two months after the evacuation. The rest of the benign cases belong to the second 
group, except for one case where it took 5 months for the hCG level to normalize. Four cases had to be ruled 
out from the analysis because of inadequate information regarding the hCG level normalization.  
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Histogram 2: Normalization of hCG in months (malignant cases) 
 
The majority (15; 78.9%) of the malignant cases belong to the second group, where the hCG level 
normalized between second and fourth month after the evacuation. There was one case, a choriocarcinoma, 
where it took only two months for the hCG level to normalize. With one persistent mole, the normalization 
occurred seven months after the evacuation.  
The most common side effects caused by methotrexate were stomatitis, rise of the aminotransferase level and 
either pain or dryness in the eyes. Two patients also described a feeling of dyspnea, and with another one of 
these patients, the treatment had to be carried out with actinomycin D. Multiple single side effects were 
reported during the use of methotrexate (Table 6). The most common side effect of actinomycin D described 
at TAYS, was nausea. Additionally, during the chemotherapy, one patient suffered from oral pain, alopecia, 
rise of aminotransferase levels, cough, urine tract infection and pneumonia. All side effects described with 
actinomycin treatment are presented in Table 6. At TAYS, EMA/CO was most often connected with 
neutropenia and paresthesia in peripheral parts of limbs. Multiple other side effects described with the use of 
EMA/CO are presented in Table 6.  
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Table 6: Side effects of the chemotherapies 
Chemotherapy Side effect Times 
reported 
Methotrexate (used 14 times)  stomatitis  4 
aminotransferase rise  
eye pain or dryness   
3 
3 
mucositis (genitals) 
stomach pain  
dyspnea  
2 
2 
2 
fever 
nausea 
neutropenia 
cough 
urticaria 
brownish fluor  
1 
1 
1 
1 
1 
1 
Actinomycin D (used 4 
times) 
nausea  2  
fatigue  
brownish fluor  
oral pain  
cough   
rash  
alopecia  
aminotransferase rise   
pneumonia  
urine tract infection  
1 
1 
1 
1 
1 
1 
1 
1 
1 
EMA/CO (used 7 times)  neutropenia 6  
paresthesia of peripheral limbs  3 
aminotransferase rise  
stomatitis 
pneumonia   
fever  
brownish fluor  
2 
2 
2 
2 
2 
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anemia  
constipation  
alopecia  
impairment of memory and concentration   
hot flashes   
mucositis   
headache  
lymph node pain  
fatigue  
sinusitis  
phlebothrombosis  
leukemia 
transient loss of vision (caused by 
methotrexate) 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
EA/CO  neutropenia   
rash  
glutamyltransferase rise  
1 
1 
1 
 
In addition to the side effects described earlier, few more severe side effects occurred at TAYS, as seen in 
Table 6. One of these was a transient loss of vision caused by methotrexate when a patient with 
choriocarcinoma was treated with EMA/CO. The loss of vision lasted for couple of hours, and the use of 
methotrexate was stopped immediately. The treatment was carried out as EA/CO, without methotrexate, until 
the patient recovered from choriocarcinoma, and no long-term harm was caused to the patient. Another 
patient, with choriocarcinoma as well, suffered from a secondary malignancy, an acute lymphatic leukemia, 
following the EMA/CO treatment. The leukemia was diagnosed a few months after EMA/CO was used, and 
with chemotherapy and allogenic stem cell transfusion, a remission was accomplished. Simultaneously with 
leukemia diagnosis, the patient was also diagnosed with phlebothrombosis. Despite the gravity of these side 
effects, the patient fully recovered and had a successful pregnancy with donor ovum some years after 
choriocarcinoma and leukemia.  
After excluding five cases with insufficient information regarding pregnancies after gestational trophoblastic 
disease, a total of 74% of the patients have had one or more successful pregnancies, or were pregnant when 
the data was collected (autumn 2014). Hysterectomy was performed to two patients in accordance to their 
own wish. One of these patients suffered from a persistent mole and another from a partial mole. When it 
comes to the rest of the cases, it is impossible to say whether there has been a connection between GTD and 
its treatment and the lack of following pregnancies, due to inadequate information.  
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A relapse occurred in three of the cases. However, one of the relapses was not treated at TAYS. All patients 
with relapsed disease fully recovered with appropriate treatment, including the case that was treated 
elsewhere. Altogether, all the patients in the research data cured, and no deaths occurred. Furthermore, no 
long-term harm followed either from gestational trophoblastic diseases or their treatment.  
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5 DISCUSSION  
 
 
A previous study, carried out in Finland between years 1962 and 1983 (published 1986), suggests that 
malignant trophoblastic diseases can be successfully treated in small units of gynecologic oncology if the 
knowledge of the modern cytotoxic principles is up to date.(10) The gynecologic unit at TAYS is a medium 
size unit. Very similar results can be received when comparing these two studies, meaning that the treatment 
in a medium size unit, such as TAYS can be very successful with appropriate, up-to-date knowledge as also 
suggested by the previous study considering smaller centers (10).  
Other studies suggest that a risk for hydatidiform mole is greater when it comes to extremities of maternal 
age, meaning ages under 20 or over 40 years old (2, 8, 9). In this study, altogether 23.6% of the patients had 
a higher risk for hydatidiform mole due to their age. An advanced maternal age is also considered to be a risk 
factor for choriocarcinoma (8). This study included only three cases of choriocarcinomas and no connection 
between advanced maternal age and incidence of choriocarcinoma was found. 
The majority of benign (91.2%) cases and 47.4% of malignant disorders were evacuated only once. There 
was also a large number of malignant disorders evacuated twice (36.8%), while benign cases managed with 
two suction curettages are notably fewer (8.8%). In addition, no benign cases needed to be evacuated three 
times. Based on these results, a conclusion can be made that neoplastic disorders treated at TAYS required 
more evacuations than benign, non-neoplastic disorders.  
Some studies suggest that more than a half of patients with a hydatidiform mole have a completely normal 
hCG level within 2 months of the evacuation (2, 8). As seen in Histogram 1, the same results were achieved 
at TAYS, with 67.3% of benign disorders having concentrations below 5 IU/l within 2 months. With the 
majority of the malignant cases (78.9%), the hCG level normalized between the second and fourth month 
after the evacuation (Histogram 2). In addition, there was one malignant case where normalization occurred 
in two months and one case where it took seven months for the hCG level to normalize. Based on these 
results, a conclusion can be made that the normalization of the hCG level is faster in hydatidiform moles 
(benign, non-neoplastic) than with malignant disorders treated at TAYS. 
The most common side effects of methotrexate described in other studies are stomatitis (1), mucositis, 
myelosuppression, rise of aminotransferase levels and pleural pain (2). All of these same side effects, except 
for pleural pain, were also common in TAYS when patients were treated with methotrexate. In addition, 
dryness or pain in the eyes was quite commonly described. With actinomycin D, the most commonly 
described side effect was nausea. Other single side effects were also reported. In other studies, the most 
common side effects of actinomycin D are nausea, alopecia (1, 3, 4) and vomiting (4). Other studies suggest 
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that the most common side effects of EMA/CO are nausea, hair loss and myelosuppression (2). At TAYS, 
multiple different side effects were reported with EMA/CO. Especially neutropenia and paresthesia of 
peripheral parts of the limbs were commonly reported, whereas alopecia was reported only once with the use 
of EMA/CO, and nausea was not reported at all. (Table 6)   
To minimize the potential bias in the study, the sample size was as large as possible by including all the 
cases treated at TAYS between 2002 and 2013. In addition, all the cases with inadequate or unclear 
information were excluded from the analysis or parts of it. A small bias can be caused by possible mistakes 
made during the registering of the medical records, or collection of the data. Because of the severity of the 
disease, all patients except one remained in care for the entire follow-up.   
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6 CONCLUSIONS   
 
 
 
All the patients suffering from gestational trophoblastic diseases treated at TAYS between years 2002 and 
2013 were cured completely, and no long-term harm was caused by the disorders or the treatments. In 
addition, 74% of the patients have had a successful pregnancy following the gestational trophoblastic 
disorder, including those who were pregnant at the time the data was collected (autumn 2014). Based on 
these results, a conclusion can be made that the cure rates accomplished with treatment at Tampere 
University Hospital, considering both benign and malignant gestational trophoblastic diseases, are 
comparable to cure rates suggested in other studies (1, 2, 5, 6, 7).  
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